TLR7 agonists also activate platelets and increase the levels of platelet-neutrophil aggregates in the bloodstream, and this effect depends on P-selectin binding to P-selectin glycoprotein ligand 1 (PSGL1), which relieve disease progression of SLE [74]. The gene discussed is SELP; the disease is systemic lupus erythematosus.